Voyager Therapeutics, Inc. - 10-Q Filing
Voyager Therapeutics filed its quarterly report for the period ended March 31, 2026, providing financial and operational updates. The report includes details on research and development programs, including the Tau Silencing Gene Therapy Program, partnered programs, and other platforms. It also outlines stock-based compensation plans, related-party transactions, and financial instruments such as commercial paper and U.S. Treasury securities.
Tickers: $VYGR